ArticleGene therapy2000
Glucose regulated production of human insulin in rat hepatocytes.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 109 citations in OpenAlex.
- Applications of Genome-Editing Technologies for Type 1 Diabetes.International journal of molecular sciences · 2023Review
- Article
- Harnessing endogenous signals from hepatocytes using a low volume multi-well plate.Integrative biology : quantitative biosciences from nano to macro · 2017Article
- Cell biology is different in small volumes: endogenous signals shape phenotype of primary hepatocytes cultured in microfluidic channels.Scientific reports · 2016Article
- Hepatic insulin gene therapy prevents diabetic enteropathy in STZ-treated CD-1 mice.Molecular therapy. Methods & clinical development · 2015Article
- Therapeutic effects of a non-β cell bioartificial pancreas in diabetic mice.Transplantation · 2014Article
- Construction of a recombinant human insulin expression vector for mammary gland-specific expression in buffalo (Bubalus bubalis) mammary epithelial cell line.Molecular biology reports · 2014Article
- Engineered insulin secretion from neuroendocrine cells isolated from human thyroid.World journal of surgery · 2014Article
- Article
- Combinatorial insulin secretion dynamics of recombinant hepatic and enteroendocrine cells.Biotechnology and bioengineering · 2012Article
- Gene regulation systems for gene therapy applications in the central nervous system.Neurology research international · 2012Article
- Construction of Plasmid Insulin Gene Vector Containing Metallothionein IIA (pcDNAMTChIns) and Carbohydrate Response Element (ChoRE), and Its Expression in NIH3T3 Cell Line.International journal of endocrinology and metabolism · 2012Article
- Delivery of a therapeutic protein by immune-privileged Sertoli cells.Cell transplantation · 2010Article
- Treatment of diabetes by transplantation of drug-inducible insulin-producing gut cells.Journal of molecular medicine (Berlin, Germany) · 2009Article
- A cell-based approach for diabetes treatment using engineered non-beta cells.Journal of diabetes science and technology · 2009Article
- Glucose- and metabolically regulated hepatic insulin gene therapy for diabetes.Pharmaceutical research · 2008Article
- Long-term correction of diabetes in rats after lentiviral hepatic insulin gene therapy.Diabetologia · 2007Article
- Coupling of glucose response element from L-type pyruvate kinase and G6Pase promoter enhances glucose responsive activity in hepatoma cells.Molecular and cellular biochemistry · 2007Article
- Gene- and cell-based therapeutics for type I diabetes mellitus.Gene therapy · 2003Review
- Glucose-modulated transgene expression via recombinant adeno-associated virus.Pharmaceutical research · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Insulin gene therapy requires that insulin secretion be coupled to metabolic requirements. To this end, we have developed an insulin transgene whose transcription is stimulated by glucose and inhibited by insulin. Glucose- and insulin-sensitive promoters were constructed by inserting glucose-responsive elements (GlREs) from the rat L-pyruvate kinase (L-PK) gene into the insulin-sensitive, liver-specific, rat insulin-like growth factor binding protein-1 (IGFBP-1) promoter. Glucose (5 to 25 mM) stimulated, and insulin (10-10 to 10-7 M) inhibited, luciferase expression driven by these promoters in primary cultured rat hepatocytes. The capacity of transfected hepatocytes to secrete mature, biologically active insulin was demonstrated using a human proinsulin cDNA (2xfur), modified to allow protein processing by endogenous endopeptidase activity. Medium conditioned by insulin-producing hepatocytes contained greater than 300 microU/ml immunoreactive insulin, while denaturing SDS-PAGE of an anti-insulin immunoprecipitate revealed bands with the mobilities of insulin A, and B chains. Biological activity of hepatocyte-produced insulin was demonstrated in a transfection assay, in which medium conditioned by insulin-producing hepatocytes exerted an effect similar to 10-7 M insulin. We then combined the glucose- and insulin-sensitive promoter with the modified human proinsulin cDNA to create a metabolically sensitive insulin transgene ((GlRE)3BP-1 2xfur). In both H4IIE hepatoma cells stably transfected with this construct, and normal rat hepatocytes (GlRE)3BP-1 2xfur-mediated insulin secretion increased in response to stimulation by glucose. Moreover, a capacity to decrease insulin production in response to diminishing glucose exposure was also demonstrated. We conclude that the transcriptional regulation of insulin production using these glucose- and insulin-sensitive constructs meets the requirements for application in a rodent model of insulin gene therapy. Gene Therapy (2000) 7, 205-214.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.